Cadrenal Therapeutics(US:CVKD) Prnewswireยท2024-10-23 13:00Core Insights - Cadrenal Therapeutics has joined the Corporate Council of the Anticoagulation Forum, emphasizing its commitment to innovation and improved patient outcomes in anticoagulation therapy [1][2]. Company Overview - Cadrenal Therapeutics is a late-stage biopharmaceutical company focused on developing tecarfarin, a new vitamin K antagonist aimed at providing safer chronic anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions [3]. - Tecarfarin is expected to result in fewer adverse events compared to warfarin, the commonly used anticoagulant, which has significant side effects and requires frequent dosing adjustments [3]. - The company has received orphan drug designation for advanced heart failure patients with implanted left ventricular assist devices (LVADs) and both orphan drug and fast-track status for end-stage kidney disease patients with atrial fibrillation [3]. - Cadrenal is planning pivotal clinical trials and is pursuing clinical and commercial partnerships, including studying tecarfarin in patients with mechanical heart valves facing anticoagulation challenges [3]. Industry Context - The Anticoagulation Forum is the largest professional organization for anticoagulation specialists, with over 15,000 members across 3,000 healthcare institutions, dedicated to enhancing the safety and quality of care for over 1 million patients annually [4]. - The forum aims to advance chronic anticoagulation care globally through education, research sharing, and advocacy initiatives [2][4].